Onconetix, Inc. (ONCO): M&A transaction — Onconetix completes Proteomedix acquisition; target shows $27.2M deficit, going concern

Onconetix, Inc.

Proteomedix 2022 revenue $392K, net loss $2.04M; accumulated deficit $27.2M as of Dec 31, 2022.
Total liabilities $6.86M vs stockholders' deficit $5.79M; cash only $470K at year-end 2022.
Auditor's report includes substantial doubt about Proteomedix's ability to continue as going concern.
Onconetix issued stock for 100% of Proteomedix equity on Dec 15, 2023; acquisition previously disclosed.
Pro forma financials and unaudited interim statements through Sep 30, 2023 now filed with SEC.

item 2.01 item 9.01 item 8.01 item 1.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Onconetix, Inc. completed an acquisition involving Proteomedix AG for share exchange (closed 2023-12-15).

Action: acquisition
Counterparty: Proteomedix AG
Consideration: share exchange
Closing: 2023-12-15

Exact text from the filing

the Company consummated a share exchange transaction (the “ Share Exchange ”) with Proteomedix on December 15, 2023.

View on SEC.gov

30 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-017544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.